UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma

PloS one, 2014-03, Vol.9 (3), p.e90353-e90353

2014

Volltextzugriff (PDF)

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group

Journal of clinical oncology, 2017-11, Vol.35 (33), p.3760-3773

2017

Volltextzugriff (PDF)

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

Journal of clinical oncology, 2010-03, Vol.28 (8), p.1301-1307

2010

Volltextzugriff (PDF)

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Journal of clinical oncology, 2009-06, Vol.27 (18), p.2954-2961

2009

Volltextzugriff (PDF)

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers

The oncologist (Dayton, Ohio), 2016-11, Vol.21 (11), p.1315-1325

2016

Volltextzugriff (PDF)

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer

Cancer and metastasis reviews, 2021-06, Vol.40 (2), p.537-547

2021

Volltextzugriff (PDF)

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-06, Vol.15 (12), p.4213-4219

2009

Volltextzugriff (PDF)

Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer

Frontiers in oncology, 2023-08, Vol.13, p.1235902-1235902

2023

Volltextzugriff (PDF)

Triple-negative breast cancer: molecular subtypes and new targets for therapy

American Society of Clinical Oncology educational book, 2015 (35), p.e31-e39

2015

Volltextzugriff (PDF)

Cutaneous Manifestations of Breast Cancer

Seminars in oncology, 2016-06, Vol.43 (3), p.331-334

Tan, Antoinette R

2016

Volltextzugriff (PDF)

Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer

Frontiers in oncology, 2020-08, Vol.10, p.1475-1475

2020

Volltextzugriff (PDF)

Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer

Expert opinion on biological therapy, 2022-03, Vol.22 (3), p.385-395

2022

Volltextzugriff (PDF)

COVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patients

Vaccine: X, 2023-08, Vol.14, p.100289-100289, Article 100289

2023

Volltextzugriff (PDF)

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Clinical cancer research, 2018-06, Vol.24 (12), p.2804-2811

2018

Volltextzugriff (PDF)

Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer?

Breast cancer research and treatment, 2009-06, Vol.115 (3), p.453-495

2009

Volltextzugriff (PDF)

Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer

Breast cancer research and treatment, 2023-09, Vol.201 (2), p.307-316

2023

Volltextzugriff (PDF)

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

JAMA oncology, 2019-08, Vol.5 (8), p.1132

2019

Volltextzugriff (PDF)

Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Neutropenia during Phase I Development of Liposome-Entrapped Paclitaxel

Clinical cancer research, 2008-09, Vol.14 (18), p.5856-5863

2008

Volltextzugriff (PDF)

Pharmacokinetics of Cetuximab After Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors

Clinical cancer research, 2006-11, Vol.12 (21), p.6517-6522

2006

Volltextzugriff (PDF)

Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial

The lancet oncology, 2019-11, Vol.20 (11), p.1587-1601

2019

Volltextzugriff (PDF)

The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer

Clinical advances in hematology & oncology, 2021-05, Vol.19 (5), p.305-315

2021

Volltextzugriff (PDF)

Personalizing aromatase inhibitor therapy in patients with breast cancer

Cancer treatment reviews, 2018-11, Vol.70, p.47-55

2018

Volltextzugriff (PDF)

Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Journal of clinical oncology, 2004-08, Vol.22 (15), p.3080-3090

2004

Volltextzugriff (PDF)

Targeted Treatment of Triple-Negative Breast Cancer

The cancer journal (Sudbury, Mass.), 2021-01, Vol.27 (1), p.50-58

2021

Volltextzugriff (PDF)

1 – 25 von 173

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(149)
Mit Volltextzugriff
(159)

Publikationsform

Artikel
(154)
Buchkapitel
(16)
Bücher
(3)

Sprache

Englisch
(173)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors

Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer

Triple-negative breast cancer: molecular subtypes and new targets for therapy

Cutaneous Manifestations of Breast Cancer

Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer

Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer

COVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patients

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer?

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Neutropenia during Phase I Development of Liposome-Entrapped Paclitaxel

Pharmacokinetics of Cetuximab After Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors

Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial

The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer

Personalizing aromatase inhibitor therapy in patients with breast cancer

Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Targeted Treatment of Triple-Negative Breast Cancer

Suchergebnisse filtern